Milestone Pharmaceuticals (MIST) News Today $1.54 +0.15 (+10.79%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.53 -0.01 (-0.65%) As of 05/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIST Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives $17.00 Average Target Price from AnalystsMay 25 at 1:13 AM | americanbankingnews.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Recommendation of "Hold" from AnalystsMilestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) has received an average rating of "Hold" from the five ratings firms that are covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and two have issued a buy rating on the company.May 24 at 11:22 AM | marketbeat.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Sold by Stonepine Capital Management LLCStonepine Capital Management LLC decreased its holdings in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 50.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 500,000 shares of thMay 20, 2025 | marketbeat.comRTW Investments LP Sells 750,000 Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST)RTW Investments LP trimmed its holdings in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 23.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,506,102 shares of the company's stock after sellingMay 18, 2025 | marketbeat.comMilestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate UpdateMay 15, 2025 | finanznachrichten.deMilestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate UpdateMay 14, 2025 | globenewswire.comLion Point Capital LP Trims Holdings in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)Lion Point Capital LP lowered its stake in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 38.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,025,806 shares of the compMay 14, 2025 | marketbeat.comMilestone Pharmaceuticals (MIST) Expected to Announce Earnings on MondayMilestone Pharmaceuticals (NASDAQ:MIST) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-milestone-pharmaceuticals-inc-stock/)May 7, 2025 | marketbeat.comBoxer Capital Management LLC Purchases Shares of 309,007 Milestone Pharmaceuticals Inc. (NASDAQ:MIST)Boxer Capital Management LLC purchased a new stake in Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 309,007 shares of the company's stock, valued at approximately $729,000. Boxer CaMay 4, 2025 | marketbeat.comNantahala Capital Management LLC Has $3.41 Million Holdings in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)Nantahala Capital Management LLC decreased its holdings in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 17.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,445,264 shares of tApril 30, 2025 | marketbeat.comMilestone Pharmaceuticals: A Golden Opportunity To Buy On Etripamil's CRL In PSVTApril 9, 2025 | seekingalpha.comMilestone Pharmaceuticals price target lowered to $10 from $25 at H.C. WainwrightApril 2, 2025 | markets.businessinsider.comTD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertaintyApril 2, 2025 | finance.yahoo.comMilestone Pharmaceuticals (MIST) was downgraded to a Hold Rating at TD CowenApril 2, 2025 | markets.businessinsider.comMilestone Pharmaceuticals Shares Hit New Low After FDA Rejects EtripamilMarch 29, 2025 | marketwatch.comMilestone Pharmaceuticals (NASDAQ:MIST) Given "Buy" Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $25.00 price objective on shares of Milestone Pharmaceuticals in a report on Friday.March 29, 2025 | marketbeat.comMilestone Pharmaceuticals Inc.: FDA Issues Complete Response Letter for Etripamil for PSVTMarch 28, 2025 | finanznachrichten.deMilestone stock tumbles after FDA letter on etripamilMarch 28, 2025 | ca.investing.comMilestone Pharmaceuticals announces FDA issued CRL for etripamilMarch 28, 2025 | markets.businessinsider.comMilestone CRL affirms integrity of clinical data, says H.C. WainwrightMarch 28, 2025 | msn.comUS FDA declines to approve Milestone's heart rhythm nasal spray; shares halveMarch 28, 2025 | msn.comMilestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s PositiveMarch 28, 2025 | msn.comUS FDA declines to approve Milestone Pharma's heart rhythm nasal sprayMarch 28, 2025 | reuters.comFDA Issues Complete Response Letter for Etripamil for PSVTMarch 28, 2025 | globenewswire.comMilestone Pharmaceuticals to present clinical data on etripamilMarch 21, 2025 | markets.businessinsider.comMilestone Pharmaceuticals: A Compelling Value Proposition For Patients And PayersMarch 21, 2025 | seekingalpha.comHC Wainwright Issues Negative Forecast for MIST EarningsMilestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Stock analysts at HC Wainwright cut their Q1 2025 earnings estimates for Milestone Pharmaceuticals in a research note issued to investors on Monday, March 17th. HC Wainwright analyst P. Trucchio now forecasts that the company will postMarch 21, 2025 | marketbeat.comMilestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of CardiologyMarch 20, 2025 | globenewswire.comHC Wainwright Issues Pessimistic Outlook for MIST EarningsMilestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Equities researchers at HC Wainwright decreased their FY2028 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a research note issued to investors on Monday, March 17th. HC Wainwright analyst P. Trucchio now anticipateMarch 20, 2025 | marketbeat.comMilestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $25.00 price target on shares of Milestone Pharmaceuticals in a research report on Monday.March 18, 2025 | marketbeat.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Sees Significant Growth in Short InterestMilestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 742,800 shares, a growth of 86.3% from the February 13th total of 398,700 shares. Based on an average trading volume of 817,700 shares, the days-to-cover ratio is presently 0.9 days. Currently, 1.5% of the company's shares are short sold.March 15, 2025 | marketbeat.comMilestone Pharmaceuticals (NASDAQ:MIST) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPSMilestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.04).March 14, 2025 | marketbeat.comMilestone Pharmaceuticals reports Q4 EPS (67c) vs ($1.39) last yearMarch 13, 2025 | markets.businessinsider.comMilestone Pharmaceuticals: Q4 Earnings SnapshotMarch 13, 2025 | sfgate.comMilestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate UpdateMarch 13, 2025 | globenewswire.comMilestone Pharmaceuticals (MIST) Projected to Post Quarterly Earnings on ThursdayMilestone Pharmaceuticals (NASDAQ:MIST) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest UpdateMilestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the recipient of a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 398,700 shares, a drop of 17.2% from the January 31st total of 481,400 shares. Based on an average daily trading volume, of 669,500 shares, the short-interest ratio is presently 0.6 days.March 6, 2025 | marketbeat.comMilestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 4, 2025 | globenewswire.comTD Cowen Keeps Their Buy Rating on Milestone Pharmaceuticals (MIST)March 1, 2025 | markets.businessinsider.comMilestone Pharmaceuticals' (MIST) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $25.00 target price on shares of Milestone Pharmaceuticals in a research report on Friday.March 1, 2025 | marketbeat.comMilestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 27, 2025 | globenewswire.comPiper Sandler Sticks to Their Buy Rating for Milestone Pharmaceuticals (MIST)February 26, 2025 | markets.businessinsider.comMilestone receives notice of allawance from USPTO on etripamil nasal sprayFebruary 19, 2025 | markets.businessinsider.comMilestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for EtripamilFebruary 19, 2025 | globenewswire.comShort Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Declines By 27.9%Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 481,400 shares, a drop of 27.9% from the January 15th total of 667,900 shares. Based on an average trading volume of 612,900 shares, the short-interest ratio is presently 0.8 days.February 15, 2025 | marketbeat.comMilestone Pharmaceuticals to host Commercial Launch Plan investor eventFebruary 11, 2025 | markets.businessinsider.comMilestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025February 11, 2025 | globenewswire.comLoss-Making Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Expected To Breakeven In The Medium-TermFebruary 3, 2025 | finance.yahoo.comWhat is HC Wainwright's Estimate for MIST Q1 Earnings?Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Stock analysts at HC Wainwright lowered their Q1 2025 earnings estimates for shares of Milestone Pharmaceuticals in a report issued on Monday, January 27th. HC Wainwright analyst P. Trucchio now anticipates that the company will post eaJanuary 29, 2025 | marketbeat.comMilestone Pharmaceuticals provides 2025 corporate outlookJanuary 29, 2025 | markets.businessinsider.com Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address MIST Media Mentions By Week MIST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MIST News Sentiment▼1.460.75▲Average Medical News Sentiment MIST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MIST Articles This Week▼31▲MIST Articles Average Week Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TERN News RNAC News TSVT News ALMS News INZY News GLUE News PVLA News LFCR News TNGX News GOSS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MIST) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
